JRPMC Journal of Rangpur Medical College • Vol. 11 No. 1 (2026): March 2026 • Pages 3-8
Published: 2026-05-17 Open Access Original Article

Febuxostat and Renal Outcomes in Stage 3-4 CKD Patients with Asymptomatic Hyperuricemia: A Prospective Observational Study

1.
Rajat Shuvra Paul
Associate Professor, Department of Nephrology, International Medical College, Gazipur, Bangladesh
2.
Dilip Kumar Roy
Ex Professor, Department of Nephrology, National Institute of Kidney Diseases & Urology (NIKDU) Dhaka, Bangladesh
3.
Habib Sadat Chowdhury
Professor and Head, Department of Biochemistry, International Medical College, Gazipur, Bangladesh

Abstract

Background
Chronic kidney disease (CKD) is commonly accompanied by asymptomatic hyperuricemia, which has been linked to faster renal deterioration.
Objective
This study evaluated whether febuxostat provides renal benefit compared with standard care in adults with stage 3–4 CKD and elevated serum uric acid.
Methods
This prospective observational study was conducted in the Department of Nephrology at the National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, from February to July 2016, on 150 adults with chronic kidney disease (CKD) Stage 3-4 and asymptomatic hyperuricemia (serum uric acid ≥7 mg/dL), allocated in equal numbers by a closed-envelope technique to either a Febuxostat group (40 mg once daily after breakfast) or a conventional-therapy group receiving standard CKD care without Febuxostat (75 patients in each group). Participants were followed at baseline, 2 months, and 4 months with repeat clinical and biochemical assessments. The primary outcome was a ≥10% decline from baseline eGFR at 4 months. Secondary outcomes included between-group differences in CKD stage distribution, mean eGFR, and serum creatinine at 2 and 4 months, change in serum uric acid, and significant adverse events (myocardial infarction, stroke, heart failure, mortality).
Results
Over four months, febuxostat was associated with better preservation of kidney function: eGFR remained higher, creatinine rose more slowly, and progression to CKD stage 5 was markedly lower. The primary endpoint, a ≥10% eGFR decline, occurred far less frequently with febuxostat, corresponding to a substantially reduced adjusted risk. Serum uric acid decreased to near-target levels, and cardiovascular events were infrequent and comparable between groups.
Conclusion
These findings indicate the short-term renoprotective potential of febuxostat in selected CKD patients, underscoring the need for longer controlled trials.

J Rang Med Col. March 2026; Vol.11, No.1: 3-8

Keywords: Febuxostat Asymptomatic hyperuricemia Chronic kidney disease (CKD) EGFR And Renal Outcomes
Full-Text Downloads:
Open Access Article License